NYSE:PKI

Stock Analysis Report

Executive Summary

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide.

Snowflake

Fundamentals

Acceptable track record with moderate growth potential.


Similar Companies

Share Price & News

How has PerkinElmer's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-0.1%

PKI

0.7%

US Life Sciences

-0.6%

US Market


1 Year Return

-10.4%

PKI

9.9%

US Life Sciences

0.6%

US Market

PKI underperformed the Life Sciences industry which returned 9.9% over the past year.

PKI underperformed the Market in United States of America which returned 0.6% over the past year.


Share holder returns

PKIIndustryMarket
7 Day-0.1%0.7%-0.6%
30 Day4.8%4.1%2.2%
90 Day-9.2%-3.2%1.1%
1 Year-10.1%-10.4%10.1%9.9%2.9%0.6%
3 Year57.7%55.9%76.4%75.0%44.6%35.2%
5 Year102.5%97.9%125.8%115.1%61.9%44.2%

Price Volatility Vs. Market

How volatile is PerkinElmer's share price compared to the market and industry in the last 5 years?


Simply Wall St News

2 weeks ago | Simply Wall St

This Insider Has Just Sold Shares In PerkinElmer, Inc. (NYSE:PKI)

Valuation

Is PerkinElmer undervalued based on future cash flows and its price relative to the stock market?

38.13x

Price to Earnings (PE) ratio


Intrinsic Value Based on Future Cash Flows

PerkinElmer's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

PerkinElmer's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

PerkinElmer is overvalued based on earnings compared to the US Life Sciences industry average.

PerkinElmer is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

PerkinElmer is poor value based on expected growth next year.


Price Based on Value of Assets

PerkinElmer is good value based on assets compared to the US Life Sciences industry average.


Next Steps

Future Growth

How is PerkinElmer expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

21.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

PerkinElmer's revenue is expected to grow by 6.3% yearly, however this is not considered high growth (20% yearly).

PerkinElmer's earnings are expected to grow significantly at over 20% yearly.

PerkinElmer's revenue growth is positive but not above the United States of America market average.

PerkinElmer's earnings growth is expected to exceed the United States of America market average.

PerkinElmer's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

PerkinElmer is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has PerkinElmer performed over the past 5 years?

3.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

PerkinElmer's year on year earnings growth rate has been positive over the past 5 years.

PerkinElmer's 1-year earnings growth exceeds its 5-year average (68.9% vs 3.7%)

PerkinElmer's earnings growth has exceeded the US Life Sciences industry average in the past year (68.9% vs 45%).


Return on Equity

PerkinElmer has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

PerkinElmer used its assets less efficiently than the US Life Sciences industry average last year based on Return on Assets.


Return on Capital Employed

PerkinElmer's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is PerkinElmer's financial position?


Financial Position Analysis

PerkinElmer is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

PerkinElmer's long term commitments exceed its cash and other short term assets.


Debt to Equity History and Analysis

PerkinElmer's level of debt (78%) compared to net worth is high (greater than 40%).

The level of debt compared to net worth has increased over the past 5 years (41.6% vs 78% today).

Debt is not well covered by operating cash flow (13.9%, less than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 5.9x coverage).


Balance Sheet

Low level of unsold assets.

Debt is not covered by short term assets, assets are 0.6x debt.


Next Steps

Dividend

What is PerkinElmer's current dividend yield, its reliability and sustainability?

0.32%

Expected Dividend Yield


Upcoming Dividend Payment

Purchase PerkinElmer before the 'Buy Limit' to receive their next dividend payment.


Dividend Yield and Payments Analysis

PerkinElmer's pays a lower dividend yield than the bottom 25% of dividend payers in United States of America (1.44%).

PerkinElmer's dividend is below the markets top 25% of dividend payers in United States of America (3.71%).

PerkinElmer is not paying a notable dividend for United States of America, therefore no need to check if the payments are stable.

PerkinElmer is not paying a notable dividend for United States of America, therefore no need to check if the payments are increasing.


Current Payout to Shareholders

No need to calculate the sustainability of PerkinElmer's dividends as it is not paying a notable one for United States of America.


Future Payout to Shareholders

No need to calculate the sustainability of PerkinElmer's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of PerkinElmer's salary, the management and board of directors tenure and is there insider trading?

3.4yrs

Average management tenure


CEO

Rob Friel (63yo)

11.6yrs

Tenure

US$13,961,376

Compensation

Mr. Robert F. Friel, also known as Rob, has been the Chairman of PerkinElmer Inc. since April 29, 2009 and also its Executive Director since January 1, 2006. He has been the Chairman of PerkinElmer LAS (Ge ...


CEO Compensation Analysis

Rob's remuneration is about average for companies of similar size in United States of America.

Rob's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.4yrs

Average Tenure

50.5yo

Average Age

The tenure for the PerkinElmer management team is about average.


Board Age and Tenure

3.9yrs

Average Tenure

61yo

Average Age

The tenure for the PerkinElmer board of directors is about average.


Insider Trading

PerkinElmer individual insiders have only sold shares in the past 3 months.


Recent Insider Transactions

SellUS$165,12003 Sep 19
Alexis Michas
EntityIndividual
Role
Lead Director
Lead Director
Shares2,000
Max PriceUS$82.56
SellUS$148,27407 Feb 19
Nicholas Lopardo
EntityIndividual
Shares1,600
Max PriceUS$92.67
SellUS$454,75004 Dec 18
Alexis Michas
EntityIndividual
Role
Lead Director
Lead Director
Shares5,000
Max PriceUS$90.95
SellUS$174,16003 Dec 18
Nicholas Lopardo
EntityIndividual
Shares2,000
Max PriceUS$87.08
SellUS$816,40014 Nov 18
Patrick Sullivan
EntityIndividual
Role
Member of the Board of Directors
Independent Director
Shares10,000
Max PriceUS$81.64
SellUS$184,45507 Nov 18
Pascale Witz
EntityIndividual
Role
Member of the Board of Directors
Director
Shares2,206
Max PriceUS$83.62
SellUS$164,24406 Nov 18
Nicholas Lopardo
EntityIndividual
Shares2,000
Max PriceUS$82.12

Ownership Breakdown


Management Team

  • Rob Friel (63yo)

    Chairman & CEO

    • Tenure: 11.6yrs
    • Compensation: US$13.96m
  • Dave Francisco

    CFO of Human Health & Corporate Treasurer

    • Tenure: 0yrs
  • Tajinder Vohra (53yo)

    Senior Vice President of Global Operations

    • Tenure: 1.6yrs
  • Joel Goldberg (50yo)

    Senior VP of Administration

    • Tenure: 11.2yrs
    • Compensation: US$3.08m
  • Andrew Okun (49yo)

    VP & Chief Accounting Officer

    • Tenure: 8.4yrs
  • Jamey Mock (42yo)

    Senior VP & CFO

    • Tenure: 1.3yrs
    • Compensation: US$4.27m
  • Daniel Tereau (51yo)

    Senior Vice President of Strategy & Business Development

    • Tenure: 3.7yrs
  • Deborah Butters (49yo)

    Senior VP & Chief Human Resources Officer

    • Tenure: 3.2yrs
  • Prahlad Singh (54yo)

    President

    • Tenure: 0.08yrs
    • Compensation: US$2.06m
  • Bryan Kipp

    Vice President of Investor Relations

    • Tenure: 0yrs

Board Members

  • Alexis Michas (61yo)

    Lead Director

    • Tenure: 0yrs
    • Compensation: US$337.01k
  • Pat Sullivan (67yo)

    Independent Director

    • Tenure: 11.6yrs
    • Compensation: US$268.76k
  • Sylvie Grégoire (58yo)

    Independent Director

    • Tenure: 4.6yrs
    • Compensation: US$265.01k
  • Rob Friel (63yo)

    Chairman & CEO

    • Tenure: 11.6yrs
    • Compensation: US$13.96m
  • Peter Barrett (66yo)

    Independent Director

    • Tenure: 7.6yrs
    • Compensation: US$276.26k
  • Frank Witney (65yo)

    Independent Director

    • Tenure: 3.2yrs
    • Compensation: US$265.01k
  • Sam Chapin (61yo)

    Independent Director

    • Tenure: 2.9yrs
    • Compensation: US$290.01k
  • Pascale Witz (52yo)

    Director

    • Tenure: 1.9yrs
    • Compensation: US$265.01k
  • Prahlad Singh (54yo)

    President

    • Tenure: 0.08yrs
    • Compensation: US$2.06m

Company Information

PerkinElmer, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: PerkinElmer, Inc.
  • Ticker: PKI
  • Exchange: NYSE
  • Founded: 1937
  • Industry: Life Sciences Tools and Services
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$9.615b
  • Shares outstanding: 111.08m
  • Website: https://www.perkinelmer.com

Number of Employees


Location

  • PerkinElmer, Inc.
  • 940 Winter Street
  • Waltham
  • Massachusetts
  • 2451
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PKINYSE (New York Stock Exchange)YesCommon StockUSUSDJan 1968
PKNDB (Deutsche Boerse AG)YesCommon StockDEEURJan 1968
0KHELSE (London Stock Exchange)YesCommon StockGBUSDJan 1968
PKI *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJan 1968

Biography

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. The company operates in two segments, Discovery & Analytical Solution ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/21 23:38
End of Day Share Price2019/09/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.